Pelthos Therapeutics Inc. (PTHS) generates news primarily around its commercial dermatology portfolio and corporate development activities. As a biopharmaceutical company focused on therapeutic products for unmet patient needs, much of its coverage relates to the launch and market uptake of ZELSUVMI (berdazimer) topical gel, 10.3%, an FDA-approved at-home treatment for molluscum contagiosum in adults and pediatric patients one year of age and older.
Investors following Pelthos can expect regular updates on product commercialization milestones, including prescription trends, prescriber adoption, and payer access for ZELSUVMI. Company press releases have highlighted commercial agreements with pharmacy benefit managers and group purchasing organizations that expand formulary coverage and patient access, as well as educational initiatives such as the Moms Against Molluscum movement aimed at caregivers managing molluscum contagiosum.
News flow also covers portfolio expansion. Pelthos has announced acquisitions of Xepi (ozenoxacin) Cream, 1%, an FDA-approved topical treatment for impetigo, and Xeglyze (abametapir), an FDA-approved topical treatment for head lice infestation. These transactions, together with planned product relaunch timelines, feature prominently in company communications as Pelthos builds a broader cutaneous infectious disease franchise.
On the corporate and financial side, Pelthos issues releases on quarterly financial results, private financings, and credit facilities. Examples include senior secured convertible notes with investors including Ligand Pharmaceuticals and a senior secured term loan facility with Horizon Technology Finance Corporation, both described as supporting commercialization of ZELSUVMI and the integration of additional products. Governance and investor relations updates, such as board appointments and participation in healthcare and investor conferences, also appear in the company’s news stream.
For readers and investors, the Pelthos news page offers a consolidated view of these developments, providing context on how the company is executing its strategy in molluscum contagiosum, impetigo, and head lice, and how financing and partnerships are aligned with its commercial objectives.
Pelthos Therapeutics (PTHS) reported third-quarter Zelsuvmi net product revenue of $15.2 million, more than doubling from the year-earlier quarter.
Revenue rose 114% year over year but fell 1% sequentially. Units dispensed reached 12,384, up 4% sequentially and 365% year over year. Net loss narrowed to $7.9 million from $16.2 million a year earlier and $23.4 million in the second quarter. Cash was $17.7 million at September 30.
Pelthos borrowed another $10.0 million in October, bringing Horizon borrowings to $40.0 million. Its Castle Creek merger is expected to close by the end of the first quarter of 2027, subject to Castle Creek stockholder approval and other closing conditions. The deal would add the late-stage D-Fi gene-modified cell therapy for dystrophic epidermolysis bullosa, a skin disease. Pelthos targets Xepi and Xeglyze launches in the first and third quarters of 2027, respectively.
Pelthos Therapeutics (NYSE American: PTHS) will report its third quarter 2026 financial results on November 12, 2026. The company will hold a conference call at 8:30 a.m. Eastern Time, followed by a question-and-answer period. Participants can join by telephone or webcast.
Pelthos Therapeutics (PTHS) signed a definitive agreement to merge with Castle Creek Biosciences, adding a late-stage skin-disease gene therapy platform. Castle Creek holders will receive 5,200,000 shares at closing, representing approximately 32.5% of Pelthos’ fully diluted shares. They may also receive up to 5,800,000 shares upon FDA approval of D-Fi, up to $300 million in milestone payments, and 80% of net proceeds from any priority review voucher awarded upon that approval.
D-Fi targets dystrophic epidermolysis bullosa, an inherited skin disease, with continued Phase 3 study planned. The combination would add cell and gene therapy capabilities to Pelthos’ three FDA-approved products. Both boards approved the transaction. Closing is expected by the end of the first quarter of 2027, subject to Castle Creek stockholder approval and other closing conditions. The combined company will retain the Pelthos name and PTHS ticker.
Pelthos Therapeutics (PTHS) signed a pharmacy benefit manager agreement expanding ZELSUVMI formulary access to an additional 24 million covered lives. The pharmacy benefit manager, which administers prescription drug benefits, added ZELSUVMI to its national list of covered medicines without prior authorization, effective October 1, 2026.
A separate regional commercial health plan update, effective in September, enhanced access for approximately 3 million covered lives. ZELSUVMI now has formulary coverage across 127 million, or 69%, of commercially covered lives, alongside Medicaid coverage of more than 70 million, or 100%, of covered lives. Pelthos launched the topical treatment in July 2025 for molluscum contagiosum, a viral skin infection, in adults and children one year of age and older.
Pelthos Therapeutics (NYSE American: PTHS) reported second quarter 2026 Zelsuvmi® net product revenue of $15.4 million, up 45% from $10.7 million in the first quarter. Total revenue was $15.6 million. Zelsuvmi units dispensed rose 48% quarter-over-quarter to 11,925 from 8,084, with 4,571 unique prescribers in the quarter.
Since its July 2025 launch, Zelsuvmi has generated $42.3 million in net sales, with 29,126 units dispensed and more than 25,000 patients treated. Pelthos ended June 30, 2026 with $24.2 million in cash and a $50 million Horizon term loan facility, $30 million drawn and potential access to an additional $10 million. Net loss was $23.4 million in Q2 2026 versus $25.1 million in Q1, and Adjusted EBITDA was a loss of $5.7 million versus $8.0 million. Total liabilities were $138.9 million and stockholders’ equity was a $1.5 million deficit.
Pelthos Therapeutics (NYSE American: PTHS) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026, and will host a conference call with a Q&A session at 8:30 a.m. Eastern Time. Investors can join via toll-free and international dial-in numbers or through a live webcast.
Pelthos Therapeutics (NYSE American: PTHS) announced that its 2026 Annual Meeting of Stockholders will be held virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on August 4, 2026 may vote at the meeting.
Pelthos expects to file its Notice of Annual Meeting and proxy statement in early August 2026. Because the 2026 meeting date is more than 30 days from the 2025 meeting anniversary, stockholder proposals under Rule 14a-8 must be received by August 3, 2026 for inclusion in the proxy materials.
Pelthos Therapeutics (NYSE American:PTHS) has been added to the Russell 3000E Growth Benchmark, Russell Microcap, and Russell Microcap Growth Benchmark indexes, effective with the US market open on June 29, 2026, following the 2026 Russell US Indexes reconstitution.
The Russell US Indexes capture up to 4,000 largest US stocks by market cap and are reconstituted semi-annually. According to Pelthos, inclusion may enhance its visibility as about $12.2 trillion in assets are benchmarked against Russell US indexes.
Pelthos Therapeutics (NYSE American:PTHS) announced that CEO Scott Plesha will present at the 2026 Jefferies Global Healthcare Conference in New York. The presentation is scheduled for 11:05 a.m. ET on June 4, 2026, followed by one-on-one investor meetings arranged through Jefferies representatives.
Pelthos Therapeutics (NYSE American:PTHS) reported first quarter 2026 results highlighted by continued growth of ZELSUVMI, its at‑home molluscum contagiosum treatment. ZELSUVMI net product revenue rose to $10.7 million from $9.1 million in Q4 2025, with units dispensed up 25% quarter over quarter.
Since launch in July 2025, ZELSUVMI has generated $26.9 million in net sales from 16,774 units. The sales force expanded from 50 to 64 territory managers. Pelthos entered a $50 million senior secured term loan with Horizon, drawing $30 million. Q1 2026 net loss was $(10.2) million versus $(21.7) million in Q4 2025; adjusted EBITDA was $(8.0) million. Cash was $32.0 million at March 31, 2026, with approximately 8.9 million shares outstanding on an as‑converted basis.